Leading a renaissance in kidney disease treatment

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease.

Year Invested: 2016
Location: Cambridge, Mass.
Visit: www.goldfinchbio.com

Recent News

May 31, 2018
Goldfinch Bio Presents Data on TRPC5 Inhibition as a Target for Proteinuric Kidney Disease and Announces GFB-887 as Lead Drug Program to treat FSGS

March 19, 2018
Goldfinch Bio to Present at BioCentury’s Future Leaders in Biotech Industry Conference

March 13, 2018
Goldfinch Bio Bolsters Leadership Team by Appointing Dr. Peter Mundel as Chief Scientific Officer and Electing Dr. Frank Maddux to Board of Directors

Read More News

Associated Team Members

Philip Reilly, M.D., J.D.
Venture Partner

Neil Exter

Abbie Celniker, Ph.D.

Eric Green, M.D., Ph.D.

Walter Kowtoniuk, Ph.D.